Ischemic Heart Disease (IHD) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

The global ischemic heart disease (IHD) drugs market size reached US$ 6.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 7.9 Billion by 2028, exhibiting a growth rate (CAGR) of 4.4% during 2023-2028.

Ischemic heart disease (IHD), also known as coronary heart disease, is a condition that damages the heart muscle by interrupting the oxygen and blood supply. It involves molecular changes in the blood vessels or sudden closure and narrowing of coronary arteries by atheroma. The disease is often characterized by chronic chest pain and severe discomfort and can be fatal if left untreated. Various drugs are used to treat IHD depending on the intensity of the case. For instance, if cholesterol-modifying medication decreases cholesterol levels in the blood, then aspirin is prescribed to reduce clotting tendencies of the blood, and beta blockers are utilized to lower the heart rate and decrease blood pressure. IHD drugs also include calcium channel blockers and ranolazine that improve the efficiency of beta blockers and prevent further progression of coronary disease.

The growing inclination of the masses towards interventional medical procedures along with extensive utilization of anti-anginal medications for the treatment of IHD is one of the key factors driving the market growth. IHD drugs are being incorporated in cardiological treatment procedures such as angioplasty, atherectomy and balloon angioplasty to ensure a healthy recovery and prevent relapse in the future. Additionally, rising consumer awareness regarding the benefits of scheduled administration of these drugs is also creating a significant impact on their demand. Lifestyle habits such as excessive alcohol consumption and smoking along with physical inactiveness are also leading to an increasing prevalence of cardiovascular diseases. Furthermore, the expanding population of geriatrics around the globe, who are severely prone to heart ailments, is also boosting the demand for IHD drugs.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global ischemic heart disease (IHD) drugs market report, along with forecasts at the global and regional level from 2023-2028. Our report has categorized the market based on disease class and drug class.

Breakup by Disease Class:

Angina Pectoris

Myocardial Infarction

Breakup by Drug Class:

Anti-Dyslipidemic Drugs

Calcium Channel Blockers

Beta-Blockers

ACE Inhibitors

ARBs

Vasodilators

Antithrombotic Agents

Breakup by Region

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Bayer AG, Eli Lilly and Company, Novartis International AG, Pfizer, Inc., Sanofi S.A., Actelion Pharmaceuticals Ltd., Baxter International Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Amgen Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., and Eisai Co., Ltd.

Key Questions Answered in This Report:

How has the global ischemic heart disease (IHD) drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global ischemic heart disease (IHD) drugs market?
What is the breakup of the market based on the disease class?
What is the breakup of the market based on the drug class?
What are the key regional markets in the global ischemic heart disease (IHD) drugs industry?
What are the various stages in the value chain of the global ischemic heart disease (IHD) drugs industry?
What are the key driving factors and challenges in the global ischemic heart disease (IHD) drugs industry?
What is the structure of the global ischemic heart disease (IHD) drugs industry and who are the key players?
What is the degree of competition in the global ischemic heart disease (IHD) drugs industry?

Product Code: SR112023A1413

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Ischemic Heart Disease (IHD) Drugs Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Disease Class

6.1 Angina Pectoris
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Myocardial Infarction
- 6.2.1 Market Trends
- 6.2.2 Market Forecast

7 Market Breakup by Drug Class

7.1 Anti-Dyslipidemic Drugs
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Calcium Channel Blockers
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Beta-Blockers
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 ACE Inhibitors
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 ARBs
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
7.6 Vasodilators
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
7.7 Antithrombotic Agents
- 7.7.1 Market Trends
- 7.7.2 Market Forecast

8 Market Breakup by Region

8.1 North America
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Europe
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Asia Pacific
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Middle East and Africa
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
8.5 Latin America
- 8.5.1 Market Trends
- 8.5.2 Market Forecast

9 SWOT Analysis

9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
- 13.3.1 Bayer AG
- 13.3.2 Eli Lilly and Company
- 13.3.3 Novartis International AG
- 13.3.4 Pfizer, Inc.
- 13.3.5 Sanofi S.A.
- 13.3.6 Actelion Pharmaceuticals Ltd.
- 13.3.7 Baxter International Inc.
- 13.3.8 Boehringer Ingelheim International GmbH
- 13.3.9 Bristol-Myers Squibb Company
- 13.3.10 Amgen Inc.
- 13.3.11 F. Hoffmann-La Roche AG
- 13.3.12 GlaxoSmithKline Plc
- 13.3.13 Merck & Co.
- 13.3.14 Eisai Co., Ltd.